# What researchers measured in a human trial of PEG-linked IGF-I

- Article ID: research-295
- Product: PEG-MGF (peg-mgf-446)
- Canonical page: https://heritagebiolabs.com/research-library/articles/295-what-researchers-measured-in-a-human-trial-of-peg-linked-igf-i
- Product collection: https://heritagebiolabs.com/research-library/products/peg-mgf
- Product page: https://heritagebiolabs.com/product/peg-mgf-446
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2017, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held by peptide bonds. Some act as signals, and chemical changes can influence how long a particular molecule remains detectable. PEG-MGF is a synthetic MGF-related peptide attached to polyethylene glycol. An older clinical trial tested the same broad kind of modification on a different substance, full-length insulin-like growth factor I. It provides an example of how persistence is measured when a defined molecule is studied in people. [1, 2]

The 2017 report described a first-in-human study in healthy volunteers of a specific modified IGF-I molecule. The researchers compared the PEG-linked compound with unmodified human IGF-I and a placebo. They followed the levels of the test molecule over time and assessed some biological responses. The modified compound remained in circulation longer under the study conditions, and it showed a different pattern of feedback on growth hormone than the unmodified comparison. [1]

Persistence in the blood is part of pharmacokinetics, the study of what the body does to a substance over time. Measuring a biological response, such as a change in a hormone, belongs to a different part of the evidence. An effect on movement, recovery or disease would require a study built to measure those outcomes. The volunteer study centered on early exposure and response for its defined investigational molecule. [1]

This is older, adjacent evidence about a full-length growth factor. PEG-MGF has a different peptide component. A result about the time course of one modified molecule is specific to the material tested, and its numerical findings cannot supply a time course for PEG-MGF. FDA’s separate record reports that the agency did not identify human exposure data for PEG-MGF. [1, 2]

## Sources

1. H. Kletzl et al. First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. Growth Hormone & IGF Research (publication 2017-01-10). <https://pubmed.ncbi.nlm.nih.gov/28110155/>
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA (record updated 2026-04-22). <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 059 - PEG-MGF.docx; article 295; content SHA-256 4783ba6d8c9990759845d138eda752aca0b750186db3f6be78fff135bca8ba70.
